Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 83, Issue 3, 2013, Pages 388-395

  Schoubben, Aurélie ^a   Blasi, Paolo ^a   Marenzoni, Maria Luisa ^a   Barberini, Lanfranco ^a   Giovagnoli, Stefano ^a   Cirotto, Carlo ^a   Ricci, Maurizio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Capreomycin supergeneric; Hydrophobic ion pair; Mycobacterium tuberculosis; Pulmonary delivery; Spray dryer

Indexed keywords

AGAR; CAPREOMYCIN; COUNTERION; LINOLEIC ACID; LINOLENIC ACID; OLEIC ACID;

ACUTE TOXICITY; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AQUEOUS SOLUTION; ARTICLE; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; EMBRYO; FLOW RATE; HISTOLOGY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LUNG TUBERCULOSIS; MORPHOLOGY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; POWDER; PROCESS DEVELOPMENT;

ANIMALS; ANTITUBERCULAR AGENTS; CAPREOMYCIN; CHICK EMBRYO; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; MYCOBACTERIUM TUBERCULOSIS; POWDERS; TUBERCULOSIS, PULMONARY;

EID: 84875209682     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.11.005     Document Type: Article

References (46)

1. B. Pinner, and M. Pinner The aetiology of tuberculosis, Dr. Robert Koch Am. Rev. Tuberc. 25 1932 285 323 (English translation of Koch R. Die aetiologie der tuberkulose. Berliner klinische Wochenschrift 19 (1882) 221-320 with an introduction by Krause AK)
2. G.B. Migliori, R. Loddenkemper, F. Blasi, and M.C. Raviglione 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science'' enough to tackle the epidemic? Eur. Respir. J. 29 2007 423 427
3. Global Tuberculosis Control: WHO Report 2011. ISBN 978 92 4 156438 0.
4. W.W. Yew, and C.C. Leung Management of multidrug-resistant tuberculosis: update Respirology 13 2008 2007 21 46
5. C. Lienhardt, A. Vernon, and M.C. Raviglione New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes Curr. Opin. Pulm. Med. 16 2010 186 193
6. L.G. Dover, and G.D. Coxon Current status and research strategies in tuberculosis drug development J. Med. Chem. 54 2011 6157 6165
7. L. Garcia-Contreras, Y.L. Wong, P. Muttil, D. Padilla, J. Sadoff, J. Derousse, W.A. Germishuizen, S. Goonesekera, K. Elbert, B.R. Bloom, R. Miller, P.B. Fourie, A. Hickey, and D. Edwards Immunization by a bacterial aerosol Proc. Natl. Acad. Sci. USA 105 2008 4656 4660
8. A.L. Oberg, R.B. Kennedy, P. Li, I.G. Ovsyannikova, and G.A. Poland Systems biology approaches to new vaccine development Curr. Opin. Immunol. 23 2011 436 443
9. P. Filippini, E. Iona, G. Piccaro, P. Peyron, O. Neyrolles, and L. Fattorini Activity of drug combinations against dormant Mycobacterium tuberculosis Antimicrob. Agents Chemother. 54 2010 2712 2715
10. P. Blasi, A. Schoubben, S. Giovagnoli, C. Rossi, and M. Ricci Fighting tuberculosis: old drugs, new formulations Expert Opin. Drug Deliv. 6 2009 977 993
11. A. Misra, A.J. Hickey, C. Rossi, G. Borchard, H. Terada, K. Makino, P.B. Fourie, and P. Colombo Inhaled drug therapy for treatment of tuberculosis Tuberculosis 91 2011 71 81
12. R.K. Verma, J.K. Mukker, R.S.P. Singh, K. Kumar, P.R.P. Verma, and A. Misra Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques Mol. Pharmaceut. 9 2012 1011 1016
13. F. Ungaro, R. d'Emmanuele di Villa Bianca, C. Giovino, A. Miro, R. Sorrentino, F. Quaglia, and M.I. La Rotonda Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs J. Control. Release 135 2009 25 34
14. D.A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M.L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer Large porous particles for pulmonary drug delivery Science 276 1997 1868 1871
15. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm. Res. 18 2001 1405 1410
16. J. Fiegel, L. Garcia-Contreras, M. Thomas, J. VerBerkmoes, K. Elbert, A. Hickey, and D. Edwards Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin Pharm. Res. 25 2008 805 811
17. L. Garcia-Contreras, J. Fiegel, M.J. Telko, K. Elbert, A. Hawi, M. Thomas, J. VerBerkmoes, W.A. Germishuizen, P.B. Fourie, A.J. Hickey, and D. Edwards Inhaled capreomycin large porous particles for the treatment of tuberculosis in the guinea pig model Antimicrob. Agents Chemother. 51 2007 2830 2836
18. L. Garcia-Contreras, P. Muttil, J.K. Fallon, M. Kabadi, R. Gerety, and A.J. Hickey Pharmacokinetics of sequential doses of capreomycin powder for inhalation in Guinea pigs Antimicrob. Agents Chemother. 56 2012 2612 2618
19. S. Giovagnoli, P. Blasi, A. Schoubben, C. Rossi, and M. Ricci Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery Int. J. Pharm. 333 2007 103 111
20. A. Schoubben, P. Blasi, S. Giovagnoli, M. Ricci, and C. Rossi Simple and scalable method for peptide inhalable powder production Eur. J. Pharm. Sci. 39 2010 53 58
21. A. Dharmadhikari, M. Kabadi, B. Gerety, B. Fourie, and E. Nardell Inhaled capreomycin for MDR-TB: clinical results Int. J. Tuberc. Lung Dis. 15 11 2011 S53
22. E.V. Nazarova, M.O. Shleeva, N.S. Morozova, Yu.K. Kudykina, G.N. Vostroknutova, A.O. Ruzhitsky, A.A. Selishcheva, G.M. Sorokoumova, V.I. Shvets, and A.S. Kaprelyants Role of lipid components in formation and reactivation of Mycobacterium smegmatis "nonculturable" cells Biochemistry 76 2011 636 644
23. A. Savarino, A. Mai, S. Norelli, S. El Daker, S. Valente, D. Rotili, L. Altucci, A.T. Palamara, and E. Garaci "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence Retrovirology 6 2009 52 61
24. D.H. Hamer Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it Curr. HIV Res. 2 2004 99 111
25. X. Li, N. Anton, C. Arpagaus, F. Belleteix, and T.F. Vandamme Nanoparticles by spray drying using innovative new technology: the Büchi Nano Spray Dryer B-90 J. Control. Release 147 2010 304 310
26. K. Schmid, C. Arpagaus, and W. Friess Evaluation of the nano spraydryer B-90 for pharmaceutical applications Pharm. Dev. Technol. 16 2011 287 294
27. A.L. Feng, M.A. Boraey, M.A. Gwin, P.R. Finlay, P.J. Kuehl, and R. Vehring Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery Int. J. Pharm. 409 2011 156 163
28. C. Rossi, G. Fardella, I. Chiappini, L. Perioli, C. Vescovi, M. Ricci, S. Giovagnoli, and S. Scuota UV spectroscopy and reverse-phase HPLC as novel methods to determine capreomycin of liposomal formulations J. Pharm. Biomed. Anal. 36 2004 249 255
29. E. Tortoli, C. Piersimoni, C. Scarparo, and D.M. Cirillo Micobatteriologia Clinica 2008 Selecta Medica Pavia, Italy pp. 161-175
30. P. Blasi, A. Schoubben, S. Giovagnoli, C. Puglia, L. Barberini, C. Cirotto, C. Rossi, and M. Ricci Colloidal dispersions for targeted brain drug delivery Eur. J. Pharm. Sci. 38 S 2009 25 26
31. C.L.L. Saw, P.W.S. Heng, and C.V. Liew Chick chorioallantoic membrane as an in situ biological membrane for pharmaceutical formulation development: a review Drug Dev. Ind. Pharm. 34 2008 1168 1177
32. A. Vargas, M. Zeisser-Labouèbe, N. Lange, R. Gurny, and F. Delie The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems Adv. Drug Deliv. Rev. 59 2007 1162 1176
33. N. Beccari, V. Mazzi, Manuale di tecnica microscopica. Guida pratica alla ricerca istologica e istochimica, Società Editrice Libraria, Milan, Italy, 1966, pp. 31-125.
34. M. Ricci, S. Giovagnoli, P. Blasi, A. Schoubben, L. Perioli, and C. Rossi Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation Int. J. Pharm. 311 2006 172 181
35. R.B. Schlesinger Comparative deposition of inhaled aerosols in experimental animals and humans: a review J. Toxicol. Environ. Health 15 1985 197 214
36. K. Bürki, I. Jeon, C. Arpagaus, and G. Betz New insights into respirable protein powder preparation using a nano spray dryer Int. J. Pharm. 408 2011 248 256
37. K. Tomoda, S. Kojima, M. Kajimoto, D. Watanabe, T. Nakajima, and K. Makino Effects of pulmonary surfactant system on rifampicin release from rifampicin loaded PLGA microspheres Colloids Surf. B: Biointerfaces 45 2005 1 6
38. D. Lu, L. Garcia-Contreras, D. Xu, S.L. Kurtz, J. Liu, M. Braunstein, D.N. McMurray, and A.J. Hickey Poly(lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B Pharm. Res. 24 2007 1834 1843
39. J.S. Patton, J.D. Brain, L.A. Davies, J. Fiegel, M. Gumbleton, K.-J. Kim, M. Sakagami, R. Vanbever, and C. Ehrhardt The particle has landed- characterizing the fate of inhaled pharmaceuticals J. Aerosol. Med. Pulm. Drug Deliv. 23 Suppl 2 2010 S71 S87
40. S. Edge, S. Mueller, R. Price, and J. Shur Factors affecting defining the quality and functionality of excipients used in the manufacture of dry powder inhaler products Drug Dev. Ind. Pharm. 34 2008 966 973
41. M.J. Telko, and A.J. Hickey Dry powder inhaler formulation Resp. Care 50 2005 1209 1227
42. A.A. Romanoff The hematopoietic, vascular, and lymphatic systems A.A. Romanoff, The Avian Embryo. Structural and Functional Development 1st ed. 1960 Macmillan Publishing Co. New York 569 678
43. A.F. Hughes, R.B. Freeman, and T. Fadem The teratogenic effects of sugars on the chick embryo J. Embryol. Exp. Morphol. 32 1974 661 674
44. T.I. Valdes, D. Kreutzer, and F. Moussy The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials J. Biomed. Mater. Res. 62 2002 273 282
45. P. Budai, L. Várnagy, S. Fejes, I.M. Somlyay, K. Linczmayer, and A. Pongrácz Irritative effects of some pesticides and a technical component on tissue structure of the chorioallantoic membrane Commun. Agric. Appl. Biol. Sci. 69 2004 807 809
46. A. Sturdy, A. Goodman, R.J. José, A. Loyse, M. O'Donoghue, O.M. Kon, M.J. Dedicoat, T.S. Harrison, L. John, M. Lipman, and G.S. Cooke Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice J. Antimicrob. Chemother. 66 2011 1815 1820